Oligonucleotide (siRNA) · Gene silencing: retinol binding protein 4 (RBP4) · developed by City Therapeutics
CITY-RBP4 is a small interfering RNA (siRNA) given by subcutaneous injection, designed to lower production of retinol binding protein 4 (RBP4). It is being studied in Stargardt disease 1 and in healthy volunteers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07836452 | Phase 1 | Stargardt Disease 1 | Recruiting | CTY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy VolunteersStargardt Disease 1STGD1
Updated Oct 25, 2026. Something wrong or missing? Report it on the CTY page.
See CTY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CTY catalysts and pipeline →